Beat Childhood Cancer offers phase I and phase II clinical trials to children battling childhood cancer. Our focus is on using precision medicine in patients at diagnosis as well as in difficult to treat relapsed and refractory cancers. Our goal is to increase survival and decrease toxicity while targeting the unique factors driving each child’s tumor.

Active/Enrolling:

NMTRC006B – An Intermediate Expanded Use Trial of DFMO – Study Record | ClinicalTrials.gov

NMTRC012 – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN) – Study Record | ClinicalTrials.gov

NMTRC014 – Neuroblastoma Maintenance Therapy Trial (NMTT) – Study Record | ClinicalTrials.gov

BCC015 – EFlornithine (DFMO) and Etoposide for Relapsed/ Refractory Neuroblastoma – Study Record | ClinicalTrials.gov

BCC016 – DFMO as Maintenance Therapy for Molecular High/ Very High Risk and Relapsed Medulloblastoma – Study Record | ClinicalTrials.gov

BCC017 – PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy (PEACH) – Study Record | ClinicalTrials.gov

BCC018 – Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma – Study Record | ClinicalTrials.gov

BCC-BIO-001 – Beat Childhood Cancer Specimen Banking and Data Registry – Study Record | ClinicalTrials.gov

BCC020 – A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 followed by a Randomized Controlled Trial of DFMO with or without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas – Study Record | ClinicalTrials.gov

BCC021 – Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors – Study Record | ClinicalTrials.gov

Coming Soon in 2024 to BCC022 and BCC023